Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Harvard Medical School, MD PhD, 2007
Internal Medicine Residency, Brigham and Women's Hospital, 2009
Hematology/Oncology Fellowship, Dana Farber Cancer Institute, 2013
Instructor in Medicine, Harvard Medical School, Dana Farber Cancer Institute
Targeting the TMPRSS2-ERG Translocation in Prostate Cancer
Approximately half of all prostate cancers contain a translocation involving the transcription factor ERG with the androgen regulated gene TMPRSS2. The TMPRSS2-ERG fusion results in androgen dependent overexpression of ERG which is not normally expressed in the prostate. Several lines of evidence demonstrate that aberrant overexpression of ERG contributes to the development of prostate cancer making it an attractive therapeutic target. However, transcription factors have historically been difficult to inhibit by conventional means. Furthermore, identifying critical TMPRSS2-ERG dependent pathways to target is difficult as ERG regulates many cellular processes. To address these challenges Dr. Takeda has developed a strategy to use gene expression signatures as a readout for TMPRSS2-ERG activity. This novel gene expression signature assay was combined with recent advances in genetics, proteomics, and chemistry to identify genes and small molecules that modulate TMPRSS2-ERG activity in prostate cancer cells. These findings will be important for understanding TMPRSS2-ERG function in prostate cancer and developing new therapeutics targeting its function.
Dana-Farber Cancer Institute450 Brookline AvenueDana 1230Boston MA, 02215Get Directions